LIVEKIDNEY.BIO is a biotechnology company developing a proprietary cell-derived delivery platform that has the potential to improve the health and life of patients while reducing the escalating economic burden of kidney disease on society. Its technology is based on sustained-release hydrogel formulations combined with AI-enabled data analytics. The company’s novel AI-based cell-derived therapy is designed to ameliorate kidney function in patients with chronic kidney disease and to improve the general medical condition of patients with Lupus. Its promising pipeline of cell therapy-based products comprises proprietary injectable hydrogel formulations delivered via an exclusive administration route. LIVEKIDNEY.BIO aims to prevent the progression of kidney disease, enabling kidney patients to live longer, fuller, and more productive lives.